‘Respiratory Inhalers Market Worth Over $33 Billion In 2017’ Says Visiongain Report

22 August 2017
Pharma

Visiongain’s new report The Global Respiratory Inhalers Market, 2017-2027: Revenue prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography 2017-2027 indicates that the Respiratory Inhalers market will see over $33bn in revenue in 2017.
The lead analyst of the report said:

“The advantages of inhalation therapy in the treatment of asthma and COPD have long since been established. In comparison to the oral and parenteral route, the drug dose required in inhalation therapy is lower and rapid onset of action is achieved with minimal unwanted systemic effects. The prevalence of asthma and COPD is growing across the globe and this is further fuelled by the growing ageing population. It is the major factor driving the growth of respiratory inhalers market. Other factors driving the market growth include technological advancements in respiratory inhalation products, growing awareness regarding respiratory diseases, and increasing disposable income in emerging economies.

However, growing pressure to reduce healthcare cost in the developed countries such as the U.S. is impeding the market growth. In addition, high cost of some types of inhalation devices (for instance, dry powder inhalers and nebulizers) is hindering the market growth in the respective product segments; especially in cost-sensitive markets. In addition to this, the market is likely to witness intense competition between generic and branded product manufacturers as some of the current blockbuster products are going off-patent across the forecast period. Thus, though sales will be increasing in terms of volume, the value market is likely to witness sluggish growth.”

The 181-page report contains 118 tables, charts and graphs that add visual analysis in order to explain developing trends within the Respiratory Inhalers. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Respiratory Inhaler submarkets, segmented by product type, with forecasts for Metered Dose Inhalers, Dry Powder Inhalers (including single-dose and multi-dose DPIs) and Nebulizers (Jet, Ultrasonic and Vibrating-Mesh Nebulizers). The respiratory inhalers market is also segmented by Indication with forecasts for Asthma and COPD, as well as other respiratory conditions.

The 181-page report offers market forecasts and analysis for 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 7 companies leading the field in respiratory inhaler market in detail.

The Global Respiratory Inhalers Market, 2017-2027: Revenue prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography 2017-2027 report will be of value to anyone who wants to better understand the respiratory inhalers market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the respiratory inhalers industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever